Anti-HLA-g antibodies, compositions comprising Anti-HLA-g antibodies, and methods of using Anti-HLA-g antibodies

Abstract

To provide anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies.SOLUTION: Provided herein are antibodies that selectively bind to HLA-G and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods. In some embodiments, the antibodies bind human HLA-G. In some embodiments, the antibodies comprise at least one CDR sequence defined by a consensus sequence provided in this disclosure. In some embodiments, the antibodies comprise one or more of an illustrative CDR, VH, or VL sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 62 / 737,666, filed September 27, 2018, the entire contents of which are incorporated herein by reference.

[0002] Provided herein are antibodies having binding specificity for HLA-G, as well as compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of using anti-HLA-G antibodies for therapeutic and diagnostic purposes. [Background technology]

[0003] The HLA-G histocompatibility antigen, class I, G, also known as human leukocyte antigen G (HLA-G), is a protein encoded by the HLA-G gene in humans. HLA-G belongs to the HLA nonclassical class I heavy chain paralogs. HLA-G is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). Membrane-bound and soluble forms of HLA-G exist.

[0004] HLA-G is normally expressed at the maternal-fetal interface and other immune-privileged sites. HLA-G is expressed in the placenta by extravillous trophoblast cells and may play a role in immune tolerance during pregnancy, whereas classical MHC class I genes (HLA-A and HLA-B) do not. Since HLA-G was first identified in placental samples, many studies have evaluated its role in pregnancy disorders such as preeclampsia and recurrent pregnancy loss. See Michita, Rafael Tomoya et al., Human Immunology. 2016, 77 (10): 892-897, which is incorporated herein by reference in its entirety, including all figures.

[0005] HLA-G has been shown to be immunosuppressive. By binding to receptors expressed on the surface of various myeloid and lymphoid cells, HLA-G can directly inhibit the function of NK cells, cytotoxic T lymphocytes, B cells, neutrophils, monocytes, macrophages, and dendritic cells. HLA-G also inhibits T and NK cell proliferation and cytolytic activity. HLA-G suppresses phagocytosis and induces the generation or expansion of regulatory T cells.

[0006] HLA-G mediates immune functions through at least three ITIM-containing inhibitory receptors: ILT2, ILT4, and KIR2DL4. On the surface of lymphoid and myeloid cells, for example, HLA-G mediates functions through ILT2. On the surface of myeloid cells, HLA-G mediates functions through ILT4. On the surface of decidual NK cells, HLA-G mediates immune functions through KIR2DL4 and ILT2.

[0007] HLA-G is an immune checkpoint target. It can directly inhibit immune cell function through receptor binding and / or trogocytosis and chemotactic damage. HLA-G can confer tumor cells greater invasive and metastatic potential. HLA-G promotes evasion of tumor immune surveillance and enhances metastasis and malignant progression. In tumor progression, HLA-G has other effects, such as inhibiting immune cell cytolysis, inducing immune cell apoptosis, and / or generating regulatory cells via receptor binding and / or trogocytosis.

[0008] HLA-G expression is upregulated in a wide range of tumors and is associated with poor prognosis and disease progression. Serum HLA-G levels are elevated in breast, lung, colorectal cancer (CRC), gastric, esophageal, neuroblastoma, cervical, and hematological cancers. HLA-G has also been found to correlate with clinical parameters in advanced disease, such as tumor metastasis, poor prognosis, immune evasion, and tumor invasiveness. HLA-G is an attractive target for diseases such as cancer. [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] Michita, Rafael Tomoyaet al., Human Immunology. 2016, 77 (10): 892-897 Summary of the Invention [Means for solving the problem]

[0010] The present specification provides an antibody that selectively binds to HLA-G. In some embodiments, the antibody binds to human HLA-G. In some embodiments, the antibody comprises at least one CDR sequence defined by the consensus sequence provided in this disclosure. In some embodiments, the antibody comprises at least one CDR sequence defined by the consensus sequence provided in this disclosure. In some embodiments, the antibody comprises at least one CDR sequence defined by the consensus sequence provided in this disclosure. H Or V L In some embodiments, the variant comprises one or more of the following:

[0011] Compositions and kits comprising the antibodies are also provided. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.

[0012] The present disclosure also provides methods for using the anti-HLA-G antibodies provided herein. In some embodiments, the methods are treatment methods. In some embodiments, the methods are analytical methods. In some embodiments, the methods are methods for purifying and / or quantifying HLA-G.

[0013] In some embodiments, the method is a diagnostic method. In some embodiments, the diagnostic method comprises or consists of detecting HLA-G expressed on tumors. In some embodiments, the diagnostic method comprises or consists of detecting soluble HLA-G. In some embodiments, the detection method comprises or consists of detecting HLA-G expression on the surface of immune cells.

[0014] In some embodiments, the antibody is used to treat a disease or condition. In some aspects, the disease or condition is selected from cancer, autoimmune disease, and infectious disease. Some aspects provide for the use of any of the antibodies or pharmaceutical compositions provided herein to treat a disease or condition selected from cancer, autoimmune disease, and infectious disease. [Brief explanation of the drawings]

[0015] [Figure 1] Figure 1 presents a table showing the avid and monomeric affinities of anti-HLA-G antibodies to recombinant HLA-G protein.

[0016] [Figure 2-1] Figures 2A and 2B present biolayer interferometry sensorgrams showing anti-HLA-G antibodies binding to HLA-G, which can be separated into three biochemical bins based on their ability to cross-block each other when tested for binding in a pairwise manner. [Figure 2-2] Figures 2A and 2B present biolayer interferometry sensorgrams showing anti-HLA-G antibodies binding to HLA-G, which can be separated into three biochemical bins based on their ability to cross-block each other when tested for binding in a pairwise manner.

[0017] [Figure 3]FIG. 3 presents biolayer interferometry sensorgrams showing antibodies that bind to HLA-G with varying levels of efficacy and block its interaction with ILT2 and ILT4.

[0018] [Figure 4] FIG. 4 shows the evaluation of anti-HLA-G antibodies that bind to naturally expressed HLA-G found on the surface of JEG-3 tumor cells.

[0019] [Figure 5-1] Figures 5A, 5B, 5C, and 5D present data showing that anti-HLA-G Fabs and antibodies restore NKL killing activity by blocking the inhibition mediated by the interaction of ILT2 or ILT4 with HLA-G. [Figure 5-2] Figures 5A, 5B, 5C, and 5D present data showing that anti-HLA-G Fabs and antibodies restore NKL killing activity by blocking the inhibition mediated by the interaction of ILT2 or ILT4 with HLA-G.

[0020] [Figure 6-1] Figure 6 presents an evaluation of anti-HLA-G antibodies to reverse HLA-G-mediated suppression of primary human cells. Figures 6A and 6B present an evaluation of phagocytosis in a human macrophage assay. Figure 6C presents an evaluation of the cytotoxic activity of primary human NK cells. Figure 6D presents an evaluation of primary human CD8+ T cell function. [Figure 6-2] Figure 6 presents an evaluation of anti-HLA-G antibodies to reverse HLA-G-mediated suppression of primary human cells. Figures 6A and 6B present an evaluation of phagocytosis in a human macrophage assay. Figure 6C presents an evaluation of the cytotoxic activity of primary human NK cells. Figure 6D presents an evaluation of primary human CD8+ T cell function. [Figure 6-3]Figure 6 presents an evaluation of anti-HLA-G antibodies to reverse HLA-G-mediated suppression of primary human cells. Figures 6A and 6B present an evaluation of phagocytosis in a human macrophage assay. Figure 6C presents an evaluation of the cytotoxic activity of primary human NK cells. Figure 6D presents an evaluation of primary human CD8+ T cell function.

[0021] [Figure 7-1] 7A and 7B show results depicting the binding values ​​of anti-HLA-G antibodies to individual recombinant HLA class Ia antigens immobilized on beads. [Figure 7-2] 7A and 7B show results depicting the binding values ​​of anti-HLA-G antibodies to individual recombinant HLA class Ia antigens immobilized on beads.

[0022] [Figure 8] FIG. 8 shows the evaluation of anti-HLA-G antibody binding to a panel of B-LCL lines of 28 HLA types.

[0023] [Figure 9] 9A and 9B show the evaluation of anti-HLA-G antibodies binding to various forms of HLA-G after site-directed mutagenesis.

[0024] [Figure 10] FIG. 10 presents evidence of tumor growth inhibition by anti-HLA-G antibodies with Fc effector function in a mouse tumor xenograft tumor model using HLA-G-expressing 721.221 cells. DETAILED DESCRIPTION OF THE INVENTION

[0025] 1.Definition Unless otherwise defined, all technical terms, notations and other scientific terms used herein are intended to have the meanings that are commonly understood by those skilled in the art in the field related to the present invention.In some cases, terms with commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be interpreted as representing a difference from what is commonly understood in the art.The techniques and procedures described or referenced herein are generally well understood and are well understood, for example, as described in Sambrook et al., Commonly employed by those skilled in the art using conventional methods, such as the widely used molecular cloning methods described in Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Where appropriate, procedures involving the use of commercially available kits and reagents are generally performed according to manufacturer-defined protocols and / or parameters unless otherwise specified.

[0026] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0027] The term "about" refers to and encompasses the stated value and a range above and below that value. In certain embodiments, the term "about" refers to the stated value ±10%, ±5%, or ±1% of the stated value. In certain embodiments, the term "about" refers to the stated value ±1 standard deviation of that value.

[0028] The term "combinations thereof" includes all possible combinations of the elements referred to by that term.

[0029] The term "immunoglobulin" refers to a class of structurally related proteins that generally contain two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In "intact immunoglobulins," all four chains are interconnected by disulfide bonds. The structure of immunoglobulins is well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region (V H ) and the heavy chain constant region (C H The heavy chain constant region typically comprises three domains: C H1 , C H2 , and C H3 Each light chain typically comprises a light chain variable region (V L ) and a light chain constant region. The light chain constant region typically comprises C L It contains one domain, abbreviated as .

[0030] The term "antibody" describes a type of immunoglobulin molecule and is used herein in the broadest sense. Antibodies specifically include intact antibodies (e.g., intact immunoglobulins) and antibody fragments and antigen-binding proteins. An antibody contains at least one antigen-binding domain. One example of an antigen-binding domain is the V H -V L The antigen-binding domain is formed by a dimer. An "HLA-G antibody," "anti-HLA-G antibody," "HLA-G Ab," "HLA-G-specific antibody," or "anti-HLA-G Ab" is an antibody described herein that specifically binds to the antigen HLA-G.

[0031] V H and V L The regions are hypervariable regions interspersed with more conserved regions. The more conserved regions are called framework regions (FR). H and V L Each of these sequences typically contains three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The CDRs are involved in antigen binding and confer antigen specificity and binding affinity to the antibody. Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, the entire contents of which are incorporated by reference.

[0032] Light chains from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of their constant domain.

[0033] Heavy chains from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further divided into subclasses based on sequence and functional differences. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0034] The amino acid sequence boundaries of the CDRs can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (the "Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (the "Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (the "Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (the "IMGT" numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 (the "AHo" numbering scheme), each of which is incorporated by reference in its entirety.

[0035] Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.

[0036] Unless otherwise specified, the numbering scheme used to identify a particular CDR herein is the Kabat / Chothia numbering scheme. Where the residues encompassed by these two numbering schemes differ, the numbering scheme will be defined as either Kabat or Chothia. [Table 1]

[0037] When referring to residues in antibody heavy chain constant regions (e.g., as reported in Kabat et al., supra), the "EU numbering scheme" is generally used. Unless otherwise stated, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

[0038] "Antibody fragments" include portions of an intact antibody, such as the antigen-binding or variable region of the intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab')2 fragments, Fab' fragments, scFv (sFv) fragments, and scFv-Fc fragments.

[0039] An "Fv" fragment comprises a non-covalently linked dimer of one heavy- and one light-chain variable domain.

[0040] A "Fab" fragment contains the heavy and light chain variable domains as well as the constant domain of the light chain and the first constant domain of the heavy chain (C H1 Fab fragments may be generated, for example, by papain digestion of a full-length antibody.

[0041] An "F(ab')2" fragment contains two Fab' fragments joined near the hinge region by a disulfide bond. F(ab')2 fragments may be generated, for example, by pepsin digestion of an intact antibody. F(ab')2 fragments can be isolated, for example, by treatment with β-mercaptoethanol.

[0042] "Single-chain Fv" or "sFv" or "scFv" antibody fragments contain V in a single polypeptide chain. H Domains and V L Contains domain. V H and V L are commonly linked by a peptide linker. Pluckthun A. (1994). Antibodies from Escherichia coli. In Rosenberg M. & Moore GP (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, the entire contents of which are incorporated by reference. An "scFv-Fc" fragment comprises an scFv linked to an Fc domain. For example, the Fc domain may be linked to the C-terminus of the scFv. The Fc domain may be linked to the Fc domain in a manner that reflects the orientation of the variable domains in the scFv (i.e., V H -V L or V L -V H ) depending on V H or V L Any suitable Fc domain known in the art or described herein may be used.

[0043] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A substantially homogeneous population of antibodies includes antibodies that are substantially similar and bind to the same epitope, typically excluding variants that may arise during the production of the monoclonal antibody. Such variants are generally present in only minor amounts. Monoclonal antibodies are typically obtained by a process that includes selecting a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further modified, for example, to improve its affinity for the target ("affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0044] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remaining heavy and / or light chain is derived from a different source or species.

[0045] "Humanized" forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. Humanized antibodies are generally human immunoglobulins (recipient antibodies) in which residues from one or more CDRs have been replaced with residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody, that has the desired specificity, affinity, or biological effect. In some cases, selected framework region residues of the recipient antibody are replaced with the corresponding framework region residues from the donor antibody. Humanized antibodies may also contain residues that are not found in either the recipient antibody or the donor antibody. Such modifications can be made to further improve antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.

[0046] A "human antibody" is one that has an amino acid sequence that corresponds to that of an antibody produced by a human or human cell, or derived from a non-human source that utilizes the human antibody repertoire or human antibody-encoding sequences (e.g., obtained from a human source or derived from a human cell). (Novo designed). Human antibodies specifically exclude humanized antibodies.

[0047] An "isolated antibody" is one that has been separated and / or recovered from components of its natural environment, which may include enzymes, hormones, and other proteinaceous or non-proteinaceous materials. In some embodiments, an isolated antibody is purified sufficiently to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example, by using a spinning cup sequencer. In some embodiments, an isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or non-reducing conditions with detection by Coomassie blue or silver staining. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody's natural environment will not be present. In some aspects, an isolated antibody is prepared by at least one purification step.

[0048] In some embodiments, the isolated antibody is at least 80%, 85%, 90%, 95%, or 99% purified by weight. In some embodiments, the isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99%, or 100% antibody by weight, with the remaining weight comprising the weight of other solutes dissolved in the solvent.

[0049] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is generally measured by the dissociation constant (K D ) Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument, or using biolayer interferometry technology, such as an Octet® instrument.

[0050] With respect to antibody binding to a target molecule, the terms "specific binding," "specifically binds," "specific for," "selectively binds," and "selective for" a particular antigen (e.g., a polypeptide target) or epitope on a particular antigen refer to binding that is measurably different from nonspecific or nonselective interactions. Specific binding can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule. Specific binding can be determined by competition with a control molecule that is similar to the target, such as an excess of unlabeled target. In such cases, specific binding is indicated when the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target.

[0051] As used herein, "k" d ”(seconds -1 The term k ) refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is k off Also called the value.

[0052] As used herein, "k" a " (M -1 × seconds -1 The term k ) refers to the association rate constant for a particular antibody-antigen interaction. This value is on Also called the value.

[0053] As used herein, "K" D The term "(M)" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. D =k d / k a .

[0054] As used herein, "K" A " (M -1 The term K ) refers to the association equilibrium constant for a particular antibody-antigen interaction. A =k a / k d .

[0055] An "affinity matured" antibody is one that has one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen compared to a parent antibody that does not have the alterations. In one embodiment, the affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies may be produced using various methods known in the art. For example, Marks et al. (Bio / Technology, 1992, 10:779-783, the entire contents of which are incorporated by reference) describe affinity matured antibodies. H and V L Affinity maturation by domain shuffling is described. Random mutagenesis of CDR and / or framework residues is described, for example, by Barbas et al. (Proc. Nat. Acad. Sci. USA, 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al., J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.

[0056] As used herein in the context of two or more antibodies, the terms "compete with" or "cross-compete with" indicate that the two or more antibodies compete for binding to an antigen (e.g., HLA-G). In one exemplary assay, HLA-G is coated on a plate, a first antibody is allowed to bind, and then a labeled second antibody is added. If the presence of the first antibody reduces the binding of the second antibody, the antibodies are competing. The term "compete with" also includes antibody combinations where one antibody reduces the binding of the other antibody, but no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit each other's binding regardless of the order of addition. In some embodiments, one antibody reduces the binding of the other antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0057] The term "epitope" refers to a portion of an antigen that can specifically bind to an antibody. Epitopes often consist of accessible amino acid residues and / or sugar side chains on the surface and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former, but not the latter, is lost in the presence of denaturing solvents. An epitope may include amino acid residues directly involved in binding and other amino acid residues not directly involved in binding. The epitope to which an antibody binds can be determined using known techniques for determining epitopes, such as, for example, testing the binding of the antibody to HLA-G variants with different point mutations.

[0058] The " identity " percentage between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequence and introducing gaps as necessary to achieve the maximum percentage of sequence identity.The alignment for determining the percentage of amino acid sequence identity can be achieved in various ways within the scope of the art, for example, by using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW or CLUSTAL OMEGA software.Those skilled in the art can determine the appropriate parameters for sequence alignment, including any algorithms required to achieve maximum alignment over the entire length of the sequence to be compared.

[0059] "Conservative substitution" or "conservative amino acid substitution" refers to the replacement of one or more amino acids with one or more chemically or functionally similar amino acids. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences with such substitutions are known as "conservatively modified variants." As examples, the following groups of amino acids are considered conservative substitutions for each other: [Table 2] [Table 3] [Table 4] [Table 5] Additional conservative substitutions can be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W.H. Freeman & Co., New York, N.Y. Antibodies generated by making one or more conservative substitutions of amino acid residues in a parent antibody are referred to as "conservatively modified variants."

[0060] The term "amino acid" refers to the 20 common naturally occurring amino acids, including alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine ​​(Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0061] "Treating" any disease or disorder or "treatment" thereof, in certain embodiments, refers to reversing the disease or disorder present in a subject. In another embodiment, "treating" or "treatment" includes reversing at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, "treating" or "treatment" includes modulating the disease or disorder physically (e.g., stabilization of discernible symptoms) or physiologically (e.g., stabilization of physical parameters), or both. In yet another embodiment, "treating" or "treatment" includes delaying or preventing the onset of the disease or disorder.

[0062] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount of an antibody or composition that, when administered to a subject, is effective in treating a disease or disorder.

[0063] As used herein, the term "subject" refers to a mammalian subject. Exemplary subjects include, but are not limited to, humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, birds, goats, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has cancer, an autoimmune disease or condition, and / or an infectious disease that can be treated using the antibodies provided herein. In some embodiments, the subject is a human suspected of having cancer, an autoimmune disease or condition, and / or an acute or chronic infectious disease. 2. Antibodies

[0064] Provided herein are antibodies that selectively bind to human HLA-G. In some embodiments, the antibodies selectively bind to the extracellular domain of human HLA-G.

[0065] In some embodiments, an antibody has one or more CDRs with a specific length in terms of the number of amino acid residues. In some embodiments, the Chothia CDR-H1 of the antibody is 6, 7, 8, or 9 residues in length. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5, 6, or 7 residues in length. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length. In some embodiments, the Kabat CDR-H2 of the antibody is 15, 16, 17, or 18 residues in length. In some embodiments, the Kabat / Chothia CDR-H3 of the antibody is 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 residues in length.

[0066] In some embodiments, the Kabat / Chothia CDR-L1 of the antibody is 9, 10, 11, 12, 13, 14, 15, or 16 residues in length. In some embodiments, the Kabat / Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some embodiments, the Kabat / Chothia CDR-L3 of the antibody is 8, 9, 10, 11, or 12 residues in length.

[0067] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.

[0068] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is IgA. In some aspects, the heavy chain is IgD. In some aspects, the heavy chain is IgE. In some aspects, the heavy chain is IgG. In some aspects, the heavy chain is IgM. In some aspects, the heavy chain is IgG1. In some aspects, the heavy chain is IgG2. In some aspects, the heavy chain is IgG3. In some aspects, the heavy chain is IgG4. In some aspects, the heavy chain is IgA1. In some aspects, the heavy chain is IgA2.

[0069] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab')2 fragment. In some aspects, the antibody fragment is a Fab' fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.

[0070] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.

[0071] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.

[0072] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from the exemplary sequences provided in this disclosure.

[0073] In some embodiments, the antibody blocks HLA-G interaction and / or binding to ITIM inhibitory receptors. In some embodiments, the antibody blocks HLA-G interaction and / or binding to ILT2. In some embodiments, the antibody blocks HLA-G interaction and / or binding to ILT4. In some embodiments, the antibody blocks HLA-G interaction and / or binding to KIR2DL4. In embodiments, the antibody binds to HLA-G but does not block the interaction between HLA-G and ILT2, ILT4, and / or KIRDL4. In some embodiments, the antibody disrupts HLA-G heterodimers and / or prevents HLA-G dimerization.

[0074] In some embodiments, the antibody inhibits immunosuppressive function. In some embodiments, the antibody inhibits HLA-G-mediated suppression of NK cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of cytotoxic T lymphocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of B cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of neutrophils. In some embodiments, the antibody inhibits HLA-G-mediated suppression of dendritic cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of macrophages. In some embodiments, the antibody inhibits HLA-G-mediated suppression of monocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of NK and / or T cell cytolysis and / or proliferation.

[0075] In some embodiments, the antibody prevents or inhibits HLA-G-mediated suppression of phagocytosis. In some embodiments, the antibody mediates HLA-G-mediated induction of regulatory T cells. In some embodiments, the antibody prevents or inhibits the generation or expansion of regulatory T cells.

[0076] The antibodies provided herein may be useful in treating various diseases and conditions, including cancer, autoimmune diseases, and infectious diseases. In some embodiments, the antibodies inhibit HLA-G function on tumor cells. In some embodiments, the antibodies inhibit HLA-G function in immune cells. In some embodiments, the antibodies inhibit HLA-G function in myeloid cells. In some embodiments, the antibodies inhibit HLA-G function in T cell subsets. In some embodiments, the antibodies inhibit metastasis. In some embodiments, the antibodies inhibit angiogenesis.

[0077] In some embodiments, the antibody competes or is capable of competing with another antibody for binding to human HLA-G. In some embodiments, the antibody comprises or consists of an antibody that can compete with a reference antibody for binding to human HLA-G, wherein the reference antibody binds to an epitope comprising positions 195, 197, and / or 198 of SEQ ID NO: 342 in the human HLA-G polypeptide. In some embodiments, the antibody and the reference antibody cross-compete or are capable of cross-competing with another antibody for binding to human HLA-G.

[0078] In some embodiments, the antibody binds to an epitope comprising positions 195, 197, and / or 198 of SEQ ID NO: 342 in a human HLA-G polypeptide. In some aspects, the epitope comprises or consists of a contiguous or non-contiguous span of amino acids including residues 195, 197, and / or 198 of the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope comprises a sequence identical to or corresponding to residues 195, 197, and / or 198 of a sequence within the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope has a sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity to a sequence within the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope has 1, 2, 3, 4, 5, 6, 7, 8, or 9 substitutions from a sequence within the sequence set forth in SEQ ID NO: 342. In some embodiments, the epitope has one, two, or three substitutions from residues of the sequence in the sequence set forth in SEQ ID NO: 342. In some embodiments, the antibody contacts any of the residues set forth in Figure 9. 2.1.CDR-H3 sequence

[0079] In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 76-101. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 76. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 78. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 79. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 80. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 81. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 83. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:91.In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101.

[0080] In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H3 sequence provided herein. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary CDR-H3 sequences provided herein. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided herein, and has one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. 2.2. V with Exemplary CDRs H array

[0081] In some embodiments, the antibody comprises a V or VL sequence comprising one or more CDR-H sequences that comprise, consist of, or consist essentially of one or more exemplary CDR-H sequences provided in this disclosure. H sequences, and variants thereof. 2.2.1. V Containing Exemplary Kabat CDRs H array

[0082] In some embodiments, the antibody comprises a V or VL sequence comprising one or more Kabat CDR-H sequences that comprise, consist of, or consist essentially of one or more exemplary Kabat CDR-H sequences provided in this disclosure. H 2.2.1.1. Kabat CDR-H3

[0083] In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence selected from SEQ ID NOs: 76-101. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 76. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 78. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 79. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 80. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:81. HIn some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 83. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:87. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:89. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:91. H In some embodiments, the antibody comprises a Kabat antibody comprising, consisting of, or consisting essentially of SEQ ID NO: 92. V containing the CDR-H3 sequence H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:94. HIn some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:97. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:99. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. H Contains arrays. Kabat CDR-H2

[0084] In some embodiments, the antibody comprises a V nucleotide sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 54-71. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 54. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 55. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:56. HIn some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:57. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:58. H In some embodiments, the antibody comprises the Kabat antibody sequence comprising, consisting of, or consisting essentially of SEQ ID NO:59. V containing the CDR-H2 sequence H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 60. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:61. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 62. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 63. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:64. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 65. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 66. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:67. H In some embodiments, the antibody comprises a V comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:68. HIn some embodiments, the antibody comprises a V comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:69. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 70. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 71. H Contains arrays. Kabat CDR-H1

[0085] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence selected from SEQ ID NOs: 18-34. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 18. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 19. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 20. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:21. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 22. H In some embodiments, the antibody comprises the Kabat antibody sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 23. V containing the CDR-H1 sequence H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:24. HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:25. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:26. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:27. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:28. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:29. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 30. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 31. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 32. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 33. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 34. H Contains arrays. 2.2.1.4.Kabat CDR-H3+Kabat CDR-H2

[0086] In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence selected from SEQ ID NOs: 76-101, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 54-71. H In some embodiments, the Kabat CDR-H3 sequence and the Kabat CDR-H2 sequence both comprise a single exemplary V sequence provided in this disclosure. H For example, in some embodiments, the sequence is from Kabat The CDR-H3 and Kabat CDR-H2 are both a single exemplary VDR selected from SEQ ID NOs: 170-200. H It is from an array. 2.2.1.5.Kabat CDR-H3+Kabat CDR-H1

[0087] In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence selected from SEQ ID NOs: 76-101, and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 18-34. H In some embodiments, the Kabat CDR-H3 sequence and the Kabat CDR-H1 sequence both comprise a single exemplary V sequence provided in this disclosure. H For example, in some embodiments, the sequence is from Kabat The CDR-H3 and Kabat CDR-H1 are both a single exemplary VDR selected from SEQ ID NOs: 170-200. H It is from an array. 2.2.1.6.Kabat CDR-H1+Kabat CDR-H2

[0088] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence selected from SEQ ID NOs: 18-34, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 54-71. H In some embodiments, the Kabat CDR-H1 sequence and the Kabat CDR-H2 sequence both comprise a single exemplary V sequence provided in this disclosure. H For example, in some embodiments, Kabat CDR-H1 and Kabat CDR-H2 are both from a single exemplary V sequence selected from SEQ ID NOs: 170-200. H It is from an array. 2.2.1.7.Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3

[0089] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence selected from SEQ ID NOs: 18-34, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 54-71, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 76-101. H In some embodiments, the Kabat CDR-H1 sequence, the Kabat The CDR-H2 sequence, and the Kabat CDR-H3 sequence are all from a single exemplary V H For example, in some embodiments, Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single exemplary V sequence selected from SEQ ID NOs: 170-200. H It is from an array.

[0090] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 18, a Kabat CDR-H2 sequence comprising SEQ ID NO: 54, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 19, a Kabat CDR-H2 sequence comprising SEQ ID NO: 55, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 77. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 20, a Kabat CDR-H2 sequence comprising SEQ ID NO: 56, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 78. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 79. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 22, a Kabat CDR-H2 sequence comprising SEQ ID NO: 58, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 80. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 60, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 82. HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO:21, a Kabat CDR-H2 sequence comprising SEQ ID NO:57, and a Kabat CDR-H3 sequence comprising SEQ ID NO:83. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO:21, a Kabat CDR-H2 sequence comprising SEQ ID NO:57, and a Kabat CDR-H3 sequence comprising SEQ ID NO:84. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 85. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 86. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 87. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 88. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 89. HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 90. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 27, a Kabat CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 90. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 28, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 91. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO:29, a Kabat CDR-H2 sequence comprising SEQ ID NO:64, and a Kabat CDR-H3 sequence comprising SEQ ID NO:92. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 93. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 30, a Kabat CDR-H2 sequence comprising SEQ ID NO: 66, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 94. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence comprising SEQ ID NO: 67, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 95. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 32, a Kabat CDR-H2 sequence comprising SEQ ID NO: 68, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 96. H In some embodiments, the antibody comprises a Kabat CDR-H1 sequence comprising SEQ ID NO: 33, a Kabat CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 97. V containing the CDR-H3 sequence HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 34, a Kabat CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 98. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 18, a Kabat CDR-H2 sequence comprising SEQ ID NO: 54, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 99. H In some embodiments, the antibody comprises the Kabat SEQ ID NO: 31 sequence. V comprising a CDR-H1 sequence, a Kabat CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 100 H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 101. H Contains arrays. 2.2.1.8. V Containing Exemplary Kabat CDRs H Array variants

[0091] In some embodiments, the V provided herein H The sequences include variants of the exemplary Kabat CDR-H3, CDR-H2, and / or CDR-H1 sequences provided in this disclosure.

[0092] In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H3 sequence provided herein. In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary Kabat CDR-H3 sequences provided herein. In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H3 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0093] In some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H2 sequences provided herein. In some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary Kabat CDR-H2 sequences provided herein. In some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H2 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0094] In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H1 sequences provided herein. In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary Kabat CDR-H1 sequences provided herein. In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H1 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. 2.2.2. V Containing Exemplary Chothia CDRs H array

[0095] In some embodiments, the antibody comprises a V or VL polypeptide comprising one or more Chothia CDR-H sequences that comprise, consist of, or consist essentially of one or more exemplary Chothia CDR-H sequences provided in this disclosure. H sequences, and variants thereof. 2.2.2.1.Chothia CDR-H3

[0096] In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 76-101. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:76. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:78. HIn some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:79. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 80. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:81. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:83. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:84. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:85. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:86. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:87. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:88. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:89. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. HIn some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:91. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:92. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:93. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:94. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. H In some embodiments, the antibody comprises the sequence Chothia V containing the CDR-H3 sequence H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:97. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:98. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:99. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. H In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. H Contains arrays. 2.2.2.2.Chothia CDR-H2

[0097] In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 38-50. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:38. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:39. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:40. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:41. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:42. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:43. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:44. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:45. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:46. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:47. HIn some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:48. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:49. H In some embodiments, the antibody comprises a V CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:50. H Contains arrays. Chothia CDR-H1

[0098] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1-14. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:1. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:3. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:4. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:5. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:6. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:7. HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:8. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:9. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 10. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 11. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 12. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 13. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 14. H Contains arrays. 2.2.2.4.Chothia CDR-H3+Chothia CDR-H2

[0099] In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 76-101, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 38-50. H In some embodiments, the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence both comprise a single exemplary V sequence provided in this disclosure. HFor example, in some embodiments, the Chothia CDR-H3 and Chothia CDR-H2 are both from a single exemplary V sequence selected from SEQ ID NOs: 170-200. H It is from an array. 2.2.2.5.Chothia CDR-H3+Chothia CDR-H1

[0100] In some embodiments, the antibody comprises a V CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 76-101, and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1-14. H In some embodiments, the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence both comprise a single exemplary V sequence provided in this disclosure. H For example, in some embodiments, the Chothia CDR-H3 and Chothia CDR-H1 are both from a single exemplary V sequence selected from SEQ ID NOs: 170-200. H It is from an array. 2.2.2.6.Chothia CDR-H1+Chothia CDR-H2

[0101] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence selected from SEQ ID NOs: 1-14, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 38-50. H In some embodiments, the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence both comprise a single exemplary V sequence provided in this disclosure. H For example, in some embodiments, Chothia CDR-H1 and Chothia CDR-H2 are both from a single exemplary V sequence selected from SEQ ID NOs: 170-200. H It is from an array. 2.2.2.7.Chothia CDR-H1+Chothia CDR-H2+Chothia CDR-H3

[0102] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence selected from SEQ ID NOs: 1-14, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 38-50, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 76-101. H In some embodiments, the Chothia CDR-H1 sequence, the Chothia CDR-H2 sequence, and the Chothia CDR-H3 sequence all comprise a single exemplary V sequence provided in this disclosure. H For example, in some embodiments, Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single exemplary V sequence selected from SEQ ID NOs: 170-200. H It is from an array.

[0103] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H1 sequence comprising SEQ ID NO: 39, V comprising a CDR-H2 sequence and a Chothia CDR-H3 sequence comprising SEQ ID NO: 77 H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:2, a Chothia CDR-H2 sequence comprising SEQ ID NO:40, and a Chothia CDR-H3 sequence comprising SEQ ID NO:78. HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:3, a Chothia CDR-H2 sequence comprising SEQ ID NO:41, and a Chothia CDR-H3 sequence comprising SEQ ID NO:79. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:4, a Chothia CDR-H2 sequence comprising SEQ ID NO:41, and a Chothia CDR-H3 sequence comprising SEQ ID NO:80. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:3, a Chothia CDR-H2 sequence comprising SEQ ID NO:41, and a Chothia CDR-H3 sequence comprising SEQ ID NO:76. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H1 sequence comprising SEQ ID NO: 42, V comprising a CDR-H2 sequence and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76 H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:2, a Chothia CDR-H2 sequence comprising SEQ ID NO:43, and a Chothia CDR-H3 sequence comprising SEQ ID NO:81. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:2, a Chothia CDR-H2 sequence comprising SEQ ID NO:42, and a Chothia CDR-H3 sequence comprising SEQ ID NO:82. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:5, a Chothia CDR-H2 sequence comprising SEQ ID NO:42, and a Chothia CDR-H3 sequence comprising SEQ ID NO:76. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:2, a Chothia CDR-H2 sequence comprising SEQ ID NO:42, and a Chothia CDR-H3 sequence comprising SEQ ID NO:81. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H1 sequence comprising SEQ ID NO: 41, V comprising a CDR-H2 sequence and a Chothia CDR-H3 sequence comprising SEQ ID NO: 83 H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:3, a Chothia CDR-H2 sequence comprising SEQ ID NO:41, and a Chothia CDR-H3 sequence comprising SEQ ID NO:84. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:6, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:85. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:6, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:86. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:7, a Chothia CDR-H2 sequence comprising SEQ ID NO:45, and a Chothia CDR-H3 sequence comprising SEQ ID NO:87. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H1 sequence comprising SEQ ID NO: 44, V comprising a CDR-H2 sequence and a Chothia CDR-H3 sequence comprising SEQ ID NO: 88 H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:8, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:89. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:7, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:90. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:9, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:90.H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:6, a Chothia CDR-H2 sequence comprising SEQ ID NO:45, and a Chothia CDR-H3 sequence comprising SEQ ID NO:91. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H1 sequence comprising SEQ ID NO: 44, V comprising a CDR-H2 sequence and a Chothia CDR-H3 sequence comprising SEQ ID NO: 92 H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:7, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:93. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 10, a Chothia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 94. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 11, a Chothia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 95. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 12, a Chothia CDR-H2 sequence comprising SEQ ID NO: 48, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 96. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 13, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 97. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 14, a Chothia CDR-H2 sequence comprising SEQ ID NO: 49, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 98. HIn some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 99. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO: 11, a Chothia CDR-H2 sequence comprising SEQ ID NO: 50, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 100. H In some embodiments, the antibody comprises a V CDR-H1 sequence comprising SEQ ID NO:6, a Chothia CDR-H2 sequence comprising SEQ ID NO:44, and a Chothia CDR-H3 sequence comprising SEQ ID NO:101. H Contains arrays. 2.2.2.8. V Containing Exemplary Chothia CDRs H Array variants

[0104] In some embodiments, the V provided herein H The sequences include variants of the exemplary Chothia CDR-H3, CDR-H2, and / or CDR-H1 sequences provided in this disclosure.

[0105] In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H3 sequence provided herein. In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary Chothia CDR-H3 sequences provided herein. In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H3 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0106] In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H2 sequences provided herein. In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary Chothia CDR-H2 sequences provided herein. In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H2 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0107] In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H1 sequences provided herein. In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary Chothia CDR-H1 sequences provided herein. In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H1 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. 2.3.V H array

[0108] In some embodiments, the antibody comprises, consists of, or consists essentially of a sequence selected from SEQ ID NOs: 170-200. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 170. HIn some embodiments, the antibody comprises a V that comprises, consists of, or consists essentially of SEQ ID NO: 171. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 172. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 173. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 174. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 175. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 176. H In some embodiments, the antibody comprises a V that comprises, consists of, or consists essentially of SEQ ID NO: 177. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 178. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 179. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 180. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 181. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 182. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 183. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 184. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 185. HIn some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 186. H In some embodiments, the antibody comprises a V that comprises, consists of, or consists essentially of SEQ ID NO: 187. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 188. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 189. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 190. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 191. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 192. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 193. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 194. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 195. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 196. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 197. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 198. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 199. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 200. H Contains arrays. 2.3.1.VH Array variants

[0109] In some embodiments, the V provided herein H The sequences are the same as those of the exemplary V H It may comprise, consist of, or consist essentially of a variant of the sequence.

[0110] In some embodiments, V H The sequences are the same as those of the exemplary V H In some embodiments, the V H The sequences are the same as those of the exemplary V H The nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity to any of the sequences.

[0111] In some embodiments, V H The sequence may be any of the exemplary V sequences provided in this disclosure with 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. H In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.4.CDR-L3 Sequence

[0112] In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 149-166. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 161. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 162. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 163. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 164.In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 165. In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 166.

[0113] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided herein. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the exemplary CDR-L3 sequences provided herein. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. 2.5. V with Exemplary CDRs L array

[0114] In some embodiments, the antibody comprises a V or VL sequence comprising one or more CDR-L sequences that comprise, consist of, or consist essentially of one or more exemplary CDR-L sequences provided in this disclosure. L sequences, and variants thereof. CDR-L3

[0115] In some embodiments, the antibody comprises a V nucleotide sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 149-166. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. LIn some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 161. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 162. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 163. LIn some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 164. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 165. L In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 166. L Contains arrays. CDR-L2

[0116] In some embodiments, the antibody comprises a V nucleotide sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 128-145. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 132. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 133. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 134. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 135. LIn some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 136. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 137. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 138. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 139. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 140. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 141. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144. L In some embodiments, the antibody comprises a V CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 145. L Contains arrays. CDR-L1

[0117] In some embodiments, the antibody comprises a V nucleotide sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 105-124. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 105. LIn some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 106. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 107. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 108. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 109. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 111. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 112. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. LIn some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. L Contains arrays. 2.5.4.CDR-L3+CDR-L2

[0118] In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 149-166, and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 128-145. L In some embodiments, the CDR-L3 sequence and the CDR-L2 sequence both comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, CDR-L3 and CDR-L2 are both from a single exemplary V sequence selected from SEQ ID NOs: 204-228. L It is from an array. 2.5.5.CDR-L3+CDR-L1

[0119] In some embodiments, the antibody comprises a V CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 149-166, and a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 105-124. L In some embodiments, the CDR-L3 sequence and the CDR-L1 sequence both comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, CDR-L3 and CDR-L1 are both from a single exemplary V sequence selected from SEQ ID NOs: 204-228. L It is from an array. 2.5.6.CDR-L1+CDR-L2

[0120] In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 105-124, and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 128-145. L In some embodiments, the CDR-L1 sequence and the CDR-L2 sequence both comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, CDR-L1 and CDR-L2 are both from a single exemplary V sequence selected from SEQ ID NOs: 204-228. L It is from an array. 2.5.7.CDR-L1+CDR-L2+CDR-L3

[0121] In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 105-124, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 128-145, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 149-166. LIn some embodiments, the CDR-L1 sequence, the CDR-L2 sequence, and the CDR-L3 sequence all comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, CDR-L1, CDR-L2, and CDR-L3 are all from a single exemplary V sequence selected from SEQ ID NOs: 204-228. L It is from an array.

[0122] In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 149. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 106, a CDR-L2 sequence comprising SEQ ID NO: 129, and a CDR-L3 sequence comprising SEQ ID NO: 150. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 107, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 151. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 108, a CDR-L2 sequence comprising SEQ ID NO: 130, and a CDR-L3 sequence comprising SEQ ID NO: 151. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 109, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence comprising SEQ ID NO: 152. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 107, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence comprising SEQ ID NO: 153. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence comprising SEQ ID NO: 151. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 133, and a CDR-L3 sequence comprising SEQ ID NO: 151. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 154. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 112, a CDR-L2 sequence comprising SEQ ID NO: 134, and a CDR-L3 sequence comprising SEQ ID NO: 155. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 113, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 156. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 114, a CDR-L2 sequence comprising SEQ ID NO: 136, and a CDR-L3 sequence comprising SEQ ID NO: 157.In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 157. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 116, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 155. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 155. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 158. (In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 155. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence comprising SEQ ID NO: 159. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence comprising SEQ ID NO: 160. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 141, and a CDR-L3 sequence comprising SEQ ID NO: 161. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 122, a CDR-L2 sequence comprising SEQ ID NO: 142, and a CDR-L3 sequence comprising SEQ ID NO: 162. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 143, and a CDR-L3 sequence comprising SEQ ID NO: 163. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 143, and a CDR-L3 sequence comprising SEQ ID NO: 164. In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 123, a CDR-L2 sequence comprising SEQ ID NO: 144, and a CDR-L3 sequence comprising SEQ ID NO: 165.In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO:124, a CDR-L2 sequence comprising SEQ ID NO:145, and a CDR-L3 sequence comprising SEQ ID NO:166. 2.5.8. V including example CDR-L L Array variants

[0123] In some embodiments, the V provided herein L The sequences include variants of the exemplary CDR-L3, CDR-L2, and / or CDR-L1 sequences provided in this disclosure.

[0124] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided herein. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the exemplary CDR-L3 sequences provided herein. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0125] In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L2 sequences provided herein. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary CDR-L2 sequences provided herein. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L2 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0126] In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L1 sequences provided herein. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary CDR-L1 sequences provided herein. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L1 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. 2.6.V L array

[0127] In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 204-228. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 204. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 205. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 206. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 207. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 208. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 209. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 210. L In some embodiments, the antibody comprises a V that comprises, consists of, or consists essentially of SEQ ID NO: 211. LIn some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 212. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 213. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 214. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 215. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 216. L In some embodiments, the antibody comprises a V that comprises, consists of, or consists essentially of SEQ ID NO: 217. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 218. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 219. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 220. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 221. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 222. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 223. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 224. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 225. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 226. LIn some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 227. L In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 228. L Contains arrays. 2.6.1.V L Array variants

[0128] In some embodiments, the V provided herein L The sequences are the same as those of the exemplary V L It may comprise, consist of, or consist essentially of a variant of the sequence.

[0129] In some embodiments, V L The sequences are the same as those of the exemplary V L In some embodiments, the V L The sequences are the same as those of the exemplary V L The nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity to any of the sequences.

[0130] In some embodiments, V L The sequence may be any of the exemplary V sequences provided in this disclosure with 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. L In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.7.Versus 2.7.1.CDR-H3-CDR-L3 Pair

[0131] In some embodiments, the antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. H and the CDR-L3 sequence is part of V L is part of.

[0132] In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of SEQ ID NOs: 76-101, and the CDR-L3 sequence comprises, consists of, or consists essentially of SEQ ID NOs: 149-166.

[0133] In some embodiments, the CDR-H3 sequence is SEQ ID NO:76 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0134] In some embodiments, the CDR-H3 sequence is SEQ ID NO:77 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0135] In some embodiments, the CDR-H3 sequence is SEQ ID NO:78 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0136] In some embodiments, the CDR-H3 sequence is SEQ ID NO:79 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0137] In some embodiments, the CDR-H3 sequence is SEQ ID NO:80 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0138] In some embodiments, the CDR-H3 sequence is SEQ ID NO:81 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0139] In some embodiments, the CDR-H3 sequence is SEQ ID NO: 82 and the CDR-L3 sequence is selected from SEQ ID NOs: 149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 149. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 150. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 151. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 152. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 153. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 154. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 155. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 156. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 157. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 158. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0140] In some embodiments, the CDR-H3 sequence is SEQ ID NO:83 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0141] In some embodiments, the CDR-H3 sequence is SEQ ID NO:84 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0142] In some embodiments, the CDR-H3 sequence is SEQ ID NO:85 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0143] In some embodiments, the CDR-H3 sequence is SEQ ID NO: 86 and the CDR-L3 sequence is selected from SEQ ID NOs: 149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 149. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 150. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 151. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 152. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 153. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 154. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 155. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 156. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 157. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 158. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0144] In some embodiments, the CDR-H3 sequence is SEQ ID NO:87 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0145] In some embodiments, the CDR-H3 sequence is SEQ ID NO:88 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0146] In some embodiments, the CDR-H3 sequence is SEQ ID NO:89 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0147] In some embodiments, the CDR-H3 sequence is SEQ ID NO:90 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0148] In some embodiments, the CDR-H3 sequence is SEQ ID NO:91 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0149] In some embodiments, the CDR-H3 sequence is SEQ ID NO:92 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0150] In some embodiments, the CDR-H3 sequence is SEQ ID NO:93 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0151] In some embodiments, the CDR-H3 sequence is SEQ ID NO:94 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0152] In some embodiments, the CDR-H3 sequence is SEQ ID NO:95 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0153] In some embodiments, the CDR-H3 sequence is SEQ ID NO:96 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0154] In some embodiments, the CDR-H3 sequence is SEQ ID NO:97 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0155] In some embodiments, the CDR-H3 sequence is SEQ ID NO:98 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0156] In some embodiments, the CDR-H3 sequence is SEQ ID NO:99 and the CDR-L3 sequence is selected from SEQ ID NOs:149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO:149. In some embodiments, the CDR-L3 sequence is SEQ ID NO:150. In some embodiments, the CDR-L3 sequence is SEQ ID NO:151. In some embodiments, the CDR-L3 sequence is SEQ ID NO:152. In some embodiments, the CDR-L3 sequence is SEQ ID NO:153. In some embodiments, the CDR-L3 sequence is SEQ ID NO:154. In some embodiments, the CDR-L3 sequence is SEQ ID NO:155. In some embodiments, the CDR-L3 sequence is SEQ ID NO:156. In some embodiments, the CDR-L3 sequence is SEQ ID NO:157. In some embodiments, the CDR-L3 sequence is SEQ ID NO:158. In some embodiments, the CDR-L3 sequence is SEQ ID NO:159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0157] In some embodiments, the CDR-H3 sequence is SEQ ID NO: 100, and the CDR-L3 sequence is selected from SEQ ID NOs: 149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 149. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 150. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 151. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 152. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 153. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 154. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 155. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 156. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 157. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 158. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166.

[0158] In some embodiments, the CDR-H3 sequence is SEQ ID NO: 101 and the CDR-L3 sequence is selected from SEQ ID NOs: 149-166. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 149. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 150. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 151. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 152. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 153. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 154. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 155. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 156. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 157. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 158. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 159. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 160. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 161. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 162. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 163. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 164. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 165. In some embodiments, the CDR-L3 sequence is SEQ ID NO: 166. 2.7.1.1. Variants of the CDR-H3-CDR-L3 Pair

[0159] In some embodiments, the CDR-H3-CDR-L3 pairs provided herein comprise variants of the exemplary CDR-H3 and / or CDR-L1 sequences provided in this disclosure.

[0160] In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H3 sequence provided herein. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any of the exemplary CDR-H3 sequences provided herein. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided herein, and has one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0161] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided herein. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the exemplary CDR-L3 sequences provided herein. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein, with one, two, or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. 2.7.2.V H -V L versus

[0162] In some embodiments, the antibody is H Array and V L Contains arrays.

[0163] In some embodiments, V H The sequence comprises, consists of, or consists essentially of SEQ ID NOs: 170-200. H is an array, and V L The sequence comprises, consists of, or consists essentially of SEQ ID NOs: 204-228. L It is an array.

[0164] In some embodiments, V H The sequence is SEQ ID NO: 170, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V LThe sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0165] In some embodiments, V H The sequence is SEQ ID NO: 171, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V LThe sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0166] In some embodiments, V H The sequence is SEQ ID NO: 172, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V LThe sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0167] In some embodiments, V H The sequence is SEQ ID NO: 173, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V LThe sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0168] In some embodiments, V H The sequence is SEQ ID NO: 174, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V LThe sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0169] In some embodiments, V H The sequence is SEQ ID NO: 175, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V LThe sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0170] In some embodiments, V H The sequence is SEQ ID NO: 176, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V LThe sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0171] In some embodiments, V H The sequence is SEQ ID NO: 177, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V LThe sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0172] In some embodiments, V H The sequence is SEQ ID NO: 178, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V LThe sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0173] In some embodiments, V H The sequence is SEQ ID NO: 179, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V LThe sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0174] In some embodiments, V H The sequence is SEQ ID NO: 180, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V LThe sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0175] In some embodiments, V H The sequence is SEQ ID NO: 181, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V LThe sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0176] In some embodiments, V H The sequence is SEQ ID NO: 182, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V LThe sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0177] In some embodiments, V H The sequence is SEQ ID NO: 183, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V LThe sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0178] In some embodiments, V H The sequence is SEQ ID NO: 184, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V LThe sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0179] In some embodiments, V H The sequence is SEQ ID NO: 185, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V LThe sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0180] In some embodiments, V H The sequence is SEQ ID NO: 186, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V LThe sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0181] In some embodiments, V H The sequence is SEQ ID NO: 187, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V LThe sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0182] In some embodiments, V H The sequence is SEQ ID NO: 188, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V LThe sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0183] In some embodiments, V H The sequence is SEQ ID NO: 189, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V LThe sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0184] In some embodiments, V H The sequence is SEQ ID NO: 190, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V LThe sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0185] In some embodiments, V H The sequence is SEQ ID NO: 191, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V LThe sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0186] In some embodiments, V H The sequence is SEQ ID NO: 192, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V LThe sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0187] In some embodiments, V H The sequence is SEQ ID NO: 193, and V L The sequence is selected from SEQ ID NOs: 204-228. LThe sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0188] In some embodiments, V H The sequence is SEQ ID NO: 194, and V LThe sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0189] In some embodiments, VH The sequence is SEQ ID NO: 195, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0190] In some embodiments, V H The sequence is SEQ ID NO: 196, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, VL The sequence is SEQ ID NO:228.

[0191] In some embodiments, V H The sequence is SEQ ID NO: 197, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, VL The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0192] In some embodiments, V H The sequence is SEQ ID NO: 198, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, VL The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0193] In some embodiments, V H The sequence is SEQ ID NO: 199, and V L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, V L The sequence is SEQ ID NO: 224. In some embodiments, VL The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228.

[0194] In some embodiments, V H The sequence is SEQ ID NO: 200, L The sequence is selected from SEQ ID NOs: 204-228. L The sequence is SEQ ID NO: 204. In some embodiments, V L The sequence is SEQ ID NO: 205. In some embodiments, V L The sequence is SEQ ID NO: 206. In some embodiments, V L The sequence is SEQ ID NO: 207. In some embodiments, V L The sequence is SEQ ID NO: 208. In some embodiments, V L The sequence is SEQ ID NO: 209. In some embodiments, V L The sequence is SEQ ID NO: 210. In some embodiments, V L The sequence is SEQ ID NO: 211. In some embodiments, V L The sequence is SEQ ID NO: 212. In some embodiments, V L The sequence is SEQ ID NO: 213. In some embodiments, V L The sequence is SEQ ID NO: 214. In some embodiments, V L The sequence is SEQ ID NO: 215. In some embodiments, V L The sequence is SEQ ID NO: 216. In some embodiments, V L The sequence is SEQ ID NO: 217. In some embodiments, V L The sequence is SEQ ID NO: 218. In some embodiments, V L The sequence is SEQ ID NO: 219. In some embodiments, V L The sequence is SEQ ID NO: 220. In some embodiments, V L The sequence is SEQ ID NO: 221. In some embodiments, V L The sequence is SEQ ID NO: 222. In some embodiments, V L The sequence is SEQ ID NO: 223. In some embodiments, VL The sequence is SEQ ID NO: 224. In some embodiments, V L The sequence is SEQ ID NO: 225. In some embodiments, V L The sequence is SEQ ID NO: 226. In some embodiments, V L The sequence is SEQ ID NO: 227. In some embodiments, V L The sequence is SEQ ID NO:228. 2.7.3.CDR-H1+CDR-H2+CDR-H3+CDR-L1+CDR-L2+CDR-L3

[0195] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 18, a Kabat CDR-H2 sequence comprising SEQ ID NO: 54, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 19, a Kabat CDR-H2 sequence comprising SEQ ID NO: 55, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 77. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 20, a Kabat CDR-H2 sequence comprising SEQ ID NO: 56, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 78. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 79. HIn some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 22, a Kabat CDR-H2 sequence comprising SEQ ID NO: 58, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 80. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 60, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 82. HIn some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 83. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 84. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 85. HIn some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 86. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 87. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 88. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 89. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 90. HIn some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 27, a Kabat CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 90. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 28, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 91. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 29, a Kabat CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 92. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 93. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 30, a Kabat CDR-H2 sequence comprising SEQ ID NO: 66, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 94. HIn some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence comprising SEQ ID NO: 67, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 95. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 32, a Kabat CDR-H2 sequence comprising SEQ ID NO: 68, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 96. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 33, a Kabat CDR-H2 sequence comprising SEQ ID NO: 69, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 97. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 34, a Kabat CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 98. H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 18, a Kabat CDR-H2 sequence comprising SEQ ID NO: 54, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 99. HIn some embodiments, the antibody comprises a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 100. Contains V H In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 101. H and a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 124, a CDR-L2 sequence comprising SEQ ID NO: 145, and a CDR-L3 sequence comprising SEQ ID NO: 166.

[0196] In some embodiments, the antibody comprises a V CDR-H1 sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 39, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 77, as well as a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 149. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 40, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 78, as well as a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 149. HIn some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence comprising SEQ ID NO: 41, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 79, as well as a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 149. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 4, a Chothia CDR-H2 sequence comprising SEQ ID NO: 41, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 80, as well as a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 149. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence comprising SEQ ID NO: 41, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 43, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 81. HIn some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 82. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 5, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 81. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence comprising SEQ ID NO: 41, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 83. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO:3, a Chothia CDR-H2 sequence comprising SEQ ID NO:41, and a Chothia CDR-H3 sequence comprising SEQ ID NO:84. HIn some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 85. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 86. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 7, a Chothia CDR-H2 sequence comprising SEQ ID NO: 45, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 87. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 88. H In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 89. HIn some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 7, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a VL sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 114, a CDR-L2 sequence comprising SEQ ID NO: 136, and a CDR-L3 sequence comprising SEQ ID NO: 157. V comprising a CDR-H2 sequence, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 90 H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 9, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 90, as well as a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence comprising SEQ ID NO: 157. V containing the CDR-H3 sequence H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 45, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 91, as well as a CDR-L1 sequence comprising SEQ ID NO: 116, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 155. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 92, as well as a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 155. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 7, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 93, as well as a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence comprising SEQ ID NO: 158. HIn some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 10, a Chothia CDR-H2 sequence comprising SEQ ID NO: 46, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 94, as well as a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence comprising SEQ ID NO: 155. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 11, a Chothia CDR-H2 sequence comprising SEQ ID NO: 47, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 95, as well as a CDR-L1 sequence comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence comprising SEQ ID NO: 159. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 12, a Chothia CDR-H2 sequence comprising SEQ ID NO: 48, a CDR-L1 sequence comprising SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence comprising SEQ ID NO: 160. V comprising a CDR-H2 sequence and a Chothia CDR-H3 sequence comprising SEQ ID NO: 96 H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 13, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 97, as well as a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 141, and a CDR-L3 sequence comprising SEQ ID NO: 161. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 14, a Chothia CDR-H2 sequence comprising SEQ ID NO: 49, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 98, as well as a CDR-L1 sequence comprising SEQ ID NO: 122, a CDR-L2 sequence comprising SEQ ID NO: 142, and a CDR-L3 sequence comprising SEQ ID NO: 162. HIn some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 99, as well as a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 143, and a CDR-L3 sequence comprising SEQ ID NO: 163. H sequence, as well as a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 143 In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 11, a Chothia CDR-H2 sequence comprising SEQ ID NO: 50, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 100. H In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 101, as well as a CDR-L1 sequence comprising SEQ ID NO: 123, a CDR-L2 sequence comprising SEQ ID NO: 144, and a CDR-L3 sequence comprising SEQ ID NO: 165. H The sequences include a CDR-L1 sequence comprising SEQ ID NO: 124, a CDR-L2 sequence comprising SEQ ID NO: 145, and a CDR-L3 sequence, a VL sequence comprising SEQ ID NO: 166. 2.7.3.1.V H -V L Paired variants

[0197] In some embodiments, the V provided herein H -V L The pair is an example V H and / or V L Includes sequence variants.

[0198] In some embodiments, V H The sequences are the same as those of the exemplary V H In some embodiments, the V HThe sequences are the same as those of the exemplary V H The nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity to any of the sequences.

[0199] In some embodiments, V H The sequence may be any of the exemplary V sequences provided in this disclosure with 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. H In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0200] In some embodiments, V L The sequences are the same as those of the exemplary V L In some embodiments, the V L The sequences are the same as those of the exemplary V L The nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity to any of the sequences.

[0201] In some embodiments, V LThe sequence may be any of the exemplary V sequences provided in this disclosure with 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. L In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.7.4.HC+LC

[0202] In some embodiments, the antibody comprises or consists of one or more heavy chains consisting of the HC sequence and one or more light chains consisting of the LC sequence, hi some embodiments, the antibody comprises or consists of two identical heavy chains consisting of the HC sequence and two identical light chains consisting of the LC sequence.

[0203] In some aspects, the HC sequence is an HC sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 232-262, and the LC sequence is an LC sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the HC sequence is an HC sequence consisting of a sequence selected from SEQ ID NOs: 232-262, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the HC sequence is an HC sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 266-296, and the LC sequence is an LC sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the HC sequence is an HC sequence consisting of a sequence selected from SEQ ID NOs: 266-296, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330.

[0204] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 232, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0205] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 233, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0206] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 234, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0207] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 235, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0208] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 236, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0209] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 237, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0210] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 238, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0211] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 239, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0212] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 240, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0213] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 241, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0214] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 242, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0215] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 243, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0216] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 244, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0217] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 245, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0218] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 246, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0219] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 247, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0220] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 248, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0221] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 249, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0222] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 250, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0223] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 251, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0224] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 252, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0225] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 253, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0226] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 254, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0227] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 255, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0228] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 256, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0229] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 257, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0230] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 258, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0231] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 259, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0232] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 260, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0233] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 261, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0234] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 262, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0235] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 266, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0236] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 267, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0237] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 268, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0238] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 269, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0239] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 270, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0240] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 271, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0241] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 272, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0242] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 273, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0243] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 274, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0244] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 275, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0245] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 276, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodiments, the LC sequence is SEQ ID NO: 328. In some embodiments, the LC sequence is SEQ ID NO: 329. In some embodiments, the LC sequence is SEQ ID NO: 330.

[0246] In some embodiments, the HC sequence is an HC sequence consisting of SEQ ID NO: 277, and the LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, the LC sequence is SEQ ID NO: 300. In some embodiments, the LC sequence is SEQ ID NO: 301. In some embodiments, the LC sequence is SEQ ID NO: 302. In some embodiments, the LC sequence is SEQ ID NO: 303. In some embodiments, the LC sequence is SEQ ID NO: 304. In some embodiments, the LC sequence is SEQ ID NO: 305. In some embodiments, the LC sequence is SEQ ID NO: 306. In some embodiments, the LC sequence is SEQ ID NO: 307. In some embodiments, the LC sequence is SEQ ID NO: 308. In some embodiments, the LC sequence is SEQ ID NO: 309. In some embodiments, the LC sequence is SEQ ID NO: 310. In some embodiments, the LC sequence is SEQ ID NO: 311. In some embodiments, the LC sequence is SEQ ID NO: 312. In some embodiments, the LC sequence is SEQ ID NO: 313. In some embodiments, the LC sequence is SEQ ID NO: 314. In some embodiments, the LC sequence is SEQ ID NO: 315. In some embodiments, the LC sequence is SEQ ID NO: 316. In some embodiments, the LC sequence is SEQ ID NO: 317. In some embodiments, the LC sequence is SEQ ID NO: 318. In some embodiments, the LC sequence is SEQ ID NO: 319. In some embodiments, the LC sequence is SEQ ID NO: 320. In some embodiments, the LC sequence is SEQ ID NO: 321. In some embodiments, the LC sequence is SEQ ID NO: 322. In some embodiments, the LC sequence is SEQ ID NO: 323. In some embodiments, the LC sequence is SEQ ID NO: 324. In some embodiments, the LC sequence is SEQ ID NO: 325. In some embodiments, the LC sequence is SEQ ID NO: 326. In some embodiments, the LC sequence is SEQ ID NO: 327. In some embodi...

Claims

[Claim 1] The invention described in the specification.

Images